In a recent update, Maxim Group has adjusted its price target for INmune Bio (INMB, Financial), lowering it significantly from $30.00 to $8.00. Despite this substantial adjustment, analyst Jason McCarthy has maintained his "Buy" rating for the biotechnology firm.
The change in the price target represents a 73.33% reduction, reflecting new evaluations by Maxim Group as of July 2, 2025. The decision to maintain the "Buy" rating suggests confidence in INmune Bio's (INMB, Financial) long-term potential, despite the immediate downward revision in the target price.
Investors and market observers will be closely monitoring INmune Bio's (INMB, Financial) performance in the coming months, following this prominent update by Maxim Group. The adjustments suggest important considerations in the company's strategy or market conditions that could impact its stock trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for INmune Bio Inc (INMB, Financial) is $12.40 with a high estimate of $21.00 and a low estimate of $0.60. The average target implies an upside of 436.98% from the current price of $2.31. More detailed estimate data can be found on the INmune Bio Inc (INMB) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, INmune Bio Inc's (INMB, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for INmune Bio Inc (INMB, Financial) in one year is $1.15, suggesting a downside of 50.2% from the current price of $2.3092. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the INmune Bio Inc (INMB) Summary page.
